Institution
Parker Institute for Cancer Immunotherapy
Recent research
- Health & MedicineOpen access
Abstract Multiple myeloma (MM) orchestrates immune evasion by subverting natural killer (NK) cell function. CD48, one of the most abundant NK-ligands on MM cells, paradoxically enhances NK-cell activation yet is associated with high-risk cytogenetics and poor patient survival. We...
- Health & MedicineOpen access
Increased B cell receptor signaling pathways in patients with melanoma correlates with a favorable clinical response to a cancer vaccine expressing multiple tumor-associated antigens. Here, we utilize phage immunoprecipitation sequencing (PhIP-seq) and Rapid Extracellular Antigen...
- Health & MedicineOpen access
Summary T cells are essential for anti-tumor immunity, but their ability to eliminate tumors depends on coordinated interactions with type 1 conventional dendritic cells (cDC1s). While cDC1s are known for cross-presenting tumor-derived antigens in lymph nodes to prime CD8+ T cell...
- BiologyOpen access
ABSTRACT Joint modeling (JM) of longitudinal and time‐to‐event (TTE) data is a powerful statistical technique that elucidates how temporal changes in a biomarker relate to TTE outcomes while accounting for study confounders. The growing use of next‐generation sequencing (NGS) in...
- Health & MedicineOpen access
Abstract We conducted a randomized surgical window-of-opportunity trial ( NCT04606316 ) in recurrent, resectable glioblastoma. Between 2021 and 2024, 71 patients were screened, and 63 were randomized (intention-to-treat [ITT] population), and 58 received study treatment. Patients...
- Health & MedicineOpen access
ABSTRACT Non‐invasive imaging of inflammation is critical for disease diagnosis, monitoring, and therapeutic evaluation. Nanobodies, due to their many unique properties, are emerging as powerful imaging agents; however, conventional non‐specific conjugation strategies often yield...